Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
Sponsor: Huahui Health
Summary
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Official title: A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)
Key Details
Gender
All
Age Range
12 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-04-22
Completion Date
2030-01-29
Last Updated
2026-06-10
Healthy Volunteers
No
Conditions
Interventions
Libevitug 20 mg/kg
Route of administration: intravenous infusion
Libevitug 10 mg/kg
Route of administration: intravenous infusion
Delayed treatment with libevitug
Route of administration: intravenous infusion
Locations (1)
The First Hospital of Jilin University
Changchun, Jilin, China